Login to Your Account



Shionogi set to file NDA, penetrate OIC market with naldemedine

By Marie Powers
News Editor

Friday, February 19, 2016

Opioid-induced constipation (OIC) is among a handful of functional gastrointestinal disorders that have galvanized drug development efforts in recent years. Shionogi & Co. Ltd. is now looking to make its mark in the space.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription